Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20812906rdf:typepubmed:Citationlld:pubmed
pubmed-article:20812906lifeskim:mentionsumls-concept:C0175677lld:lifeskim
pubmed-article:20812906lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20812906lifeskim:mentionsumls-concept:C1335872lld:lifeskim
pubmed-article:20812906lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:20812906lifeskim:mentionsumls-concept:C0524851lld:lifeskim
pubmed-article:20812906lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:20812906lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:20812906pubmed:issue1lld:pubmed
pubmed-article:20812906pubmed:dateCreated2011-3-11lld:pubmed
pubmed-article:20812906pubmed:abstractTextIn the etiology of brain injury associated to ischemia/reperfusion (I/R) and neurodegenerative diseases, a critical involvement of excessive activation of signal transducer and activator of transcription 1 (STAT1) and successive induction of iNOS expression has widely been evidenced. Any compound capable to down-regulate STAT1 activation seems to represent a new, promising anti-inflammatory drug. Among plant compounds, only a few have shown to possess anti-STAT1 activity. Among them, epigallocatechin-3-gallate (EGCG), the main polyphenol present in green tea leaves, efficiently protects heart from I/R injury and this action is strictly correlated to its anti-STAT1 property. Hyperforin, the non-polyphenolic compound present in St. John's wort, attenuates β-cell death induced by interferon-γ (IFN-γ) by strongly down-regulating STAT1 activation. STAT1, therefore, seems to represent a new molecular target of the protective treatment also against brain injury associated to a number of brain pathologies. Either understanding the molecular mechanism of anti-STAT1 action of these compounds or identification of other anti-STAT1 compounds are urged.lld:pubmed
pubmed-article:20812906pubmed:languageenglld:pubmed
pubmed-article:20812906pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:citationSubsetIMlld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20812906pubmed:statusMEDLINElld:pubmed
pubmed-article:20812906pubmed:monthMarlld:pubmed
pubmed-article:20812906pubmed:issn1875-6166lld:pubmed
pubmed-article:20812906pubmed:authorpubmed-author:SuzukiHHlld:pubmed
pubmed-article:20812906pubmed:authorpubmed-author:CavalieriEElld:pubmed
pubmed-article:20812906pubmed:authorpubmed-author:MariottoSSlld:pubmed
pubmed-article:20812906pubmed:authorpubmed-author:EbnerF HFHlld:pubmed
pubmed-article:20812906pubmed:authorpubmed-author:DarraEElld:pubmed
pubmed-article:20812906pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20812906pubmed:day1lld:pubmed
pubmed-article:20812906pubmed:volume11lld:pubmed
pubmed-article:20812906pubmed:ownerNLMlld:pubmed
pubmed-article:20812906pubmed:authorsCompleteYlld:pubmed
pubmed-article:20812906pubmed:pagination2-7lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:meshHeadingpubmed-meshheading:20812906...lld:pubmed
pubmed-article:20812906pubmed:year2011lld:pubmed
pubmed-article:20812906pubmed:articleTitleUse of STAT1 inhibitors in the treatment of brain I/R injury and neurodegenerative diseases.lld:pubmed
pubmed-article:20812906pubmed:affiliationDipartimento di Scienze Morfologico-Biomediche, Università di Verona, Verona, Italy.lld:pubmed
pubmed-article:20812906pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20812906pubmed:publicationTypeReviewlld:pubmed